Cancer Biopsy Demand Soars Amid Rising Cancer Rates

The cancer biopsy market is on track for substantial growth between 2025 and 2035, propelled by the steady rise in global cancer incidence. Estimated at USD 34.1 billion in 2025, the market is projected to reach USD 77.5 billion by 2035, representing a robust compound annual growth rate (CAGR) of 7.7%. This growth reflects both the increasing need for accurate, early cancer diagnosis and the evolution of biopsy techniques. 

The Role of Biopsies in Modern Oncology 

A cancer biopsy remains one of the most critical tools in cancer diagnosis and management. It involves the extraction of tissue or cell samples from a suspicious area to confirm the presence of cancer. Beyond diagnosis, biopsies help determine the type, grade, and stage of cancer, guiding treatment strategies and predicting outcomes. 

Request Sample Copy: https://wemarketresearch.com/reports/request-free-sample-pdf/cancer-biopsy-market/1695  

Market Segments 

By Product 

Instruments 

Kits & Consumables 

Others 

Type of Biopsy 

Needle Biopsy 

Endoscopic Biopsy 

Skin Biopsy 

Bone Marrow Biopsy 

Surgical Biopsy 

Endometrial Biopsy 

Others 

By Application   

Breast Cancer 

Colorectal Cancer 

Cervical Cancers 

Lung Cancers 

Prostate Cancers 

Skin Cancers 

Blood Cancers 

Others 

By End-user 

Hospital & Clinics 

Diagnostic Centres 

Academic & Research Institutes 

There are several types of biopsy procedures tailored to specific clinical contexts. The most common include: 

Needle Biopsies: These are minimally invasive and typically performed with local anesthesia. Fine-needle aspiration (FNA) removes fluid or small cell samples using a thin needle, while core needle biopsy (CNB) extracts a larger tissue sample for detailed analysis. 

Surgical Biopsies: These are more invasive and are often done when other methods fail to provide conclusive results. An excisional biopsy removes the entire tumor, while an incisional biopsy takes a portion of the tumor for testing. 

Endoscopic Biopsies: These are performed using a flexible tube with a camera to reach internal organs such as the lungs, stomach, or colon. This approach allows for targeted sampling with minimal disruption. 

Liquid Biopsies: A newer, rapidly advancing field, liquid biopsies analyze cancer-related biomarkers in body fluids like blood. This non-invasive technique is proving invaluable for early detection, ongoing monitoring, and even screening for multiple types of cancers. 

Beyond Diagnosis: Biopsies in Treatment and Monitoring 

The significance of biopsies extends well beyond initial diagnosis. In cancer staging, biopsy results help determine how far the disease has progressed, which directly influences treatment decisions. For example, localized cancers may be treated with surgery or localized radiation, while advanced-stage cancers might require systemic treatments like chemotherapy or immunotherapy. 

Biopsies are also used to identify specific tumor markers, helping oncologists tailor treatments to individual patients. This personalized approach—especially vital in the era of targeted therapies and precision medicine—relies heavily on accurate tissue analysis. 

In addition, biopsies play a key role in assessing treatment response. Repeated biopsies or liquid biopsies can reveal whether a therapy is working, allowing for timely adjustments. This dynamic use of biopsies is reshaping how clinicians manage cancer, turning static treatment plans into responsive strategies. 

Key Players:  

QIAGEN         

Epigenomics AG 

BD (Becton, Dickinson and Company) 

Biocept, Inc. 

Danaher 

Exact Sciences Corporation 

F. Hoffmann-La Roche Ltd. 

Freenome Holdings, Inc. 

GRAIL, Inc. 

Guardant Health Inc. 

Hologic, Inc. 

Illumina, Inc. 

Lucence Health Inc. 

Myriad Genetics, Inc. 

Thermo Fisher Scientific, Inc. 

What’s Fueling the Market Growth? 

The rise in cancer incidence is the primary driver. According to global health data, cancer cases are expected to continue climbing due to aging populations, lifestyle changes, and environmental factors. More cancer cases mean more demand for diagnostics—and biopsies are at the front line. 

Technological advancements are also pushing the market forward. Liquid biopsy technology, in particular, is becoming more reliable, accessible, and widely adopted. As these methods gain regulatory approval and clinical validation, their use is expanding in both developed and emerging markets. 

Other contributing factors include: 

Growing Awareness: Public health campaigns and improved access to screening programs are increasing the number of people seeking diagnostic testing early. 

Healthcare Infrastructure Development: Expanding diagnostic facilities and investment in oncology services, especially in developing regions, are fueling demand. 

Precision Medicine Growth: As oncology becomes more personalized, the need for biomarker-rich biopsy samples grows. This demand feeds into both traditional and liquid biopsy markets. 

Challenges Ahead 

Despite strong growth prospects, the cancer biopsy market faces hurdles. Traditional biopsies can be invasive, costly, and carry risks of complications. Liquid biopsy, while promising, still faces challenges in sensitivity and standardization. Regulatory complexities and reimbursement issues can also hinder market adoption, particularly in lower-income regions. 

Outlook: The 2025–2035 window looks promising for the cancer biopsy market. With innovations in biopsy techniques, rising awareness, and increasing cancer prevalence, the market is poised for sustained expansion. As non-invasive methods become more accurate and cost-effective, they may redefine cancer diagnosis and monitoring altogether. 

Explore New Updated Reports:    

Travel Insurance Market: https://wemarketresearch.com/reports/travel-insurance-market/775 

Liquid Biopsy Market: https://wemarketresearch.com/reports/liquid-biopsy-market/607 

Digital Pathology Market: https://wemarketresearch.com/reports/digital-pathology-market/62 

About We Market Research:    

At We Market Research, we are passionate about data, insights, and helping businesses thrive in an ever-evolving marketplace. Our journey began with a simple yet profound belief: Informed decisions lead to sustainable success. With this principle at our core, we've grown into a dynamic and innovative market research company dedicated to providing you with the knowledge and strategies you need to navigate the complexities of your industry.   

We provide a comprehensive range of research services, including brand perception research, pricing analysis, customer segmentation, competitive analysis, product development and innovation studies, market sizing and forecasts, and more. Our objective is to give our clients a comprehensive insight of their market environment so they can improve their competitive advantage, optimize their strategy, and drive growth.   

Contact Us:   

Robbin Joseph   

Phone: +17246183925  

Email: sales@wemarketresearch.com   

Location: United States 99 WALL STREET, #2124 NEW YORK, NY 10005